It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cigarette smoking delivers a number of heavy metals, including cadmium (Cd), into the body. Bioaccumulation may result in an increase in pathological consequences over time. The assessment of changes in serum Cd concentrations during the treatment of cigarette dependence with cytisine was performed for the first time. Parameters assessing smoking habits, strength of addiction, and effectiveness of therapy were analyzed. Cd was determined before, during, and after the end of treatment. The serum Cd levels were significantly higher in the smokers than in the nonsmokers. Significant differences in Cd concentrations between sampling times in smokers were observed. Individuals who stopped smoking had significantly lower Cd concentrations compared to baseline. A significant positive correlation between the serum Cd before treatment and smoking urges was also obtained. Additionally, salivary Cd determinations were performed before treatment to evaluate the use of this method to assess cigarette addiction. Our findings indicate that Cd can be used as a biomarker of smoking addiction, and provide an alternative assessment of tobacco smoke exposure to other methods. The results provide new knowledge related to Cd concentrations in human body fluids and may play a role in monitoring and assessing the efficacy of cytisine for smoking cessation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Rzeszów, Laboratory of Commercial and Non-Commercial Clinical Trials, Rzeszow, Poland (GRID:grid.13856.39) (ISNI:0000 0001 2154 3176); University of Rzeszów, Laboratory for Innovative Research in Pharmacology, Rzeszow, Poland (GRID:grid.13856.39) (ISNI:0000 0001 2154 3176)
2 Medical University of Lublin, Department of Pathobiochemistry and Interdisciplinary Applications of Ion Chromatography, Chair of Biomedical Sciences, Lublin, Poland (GRID:grid.411484.c) (ISNI:0000 0001 1033 7158)
3 University of Rzeszów, Laboratory for Innovative Research in Pharmacology, Rzeszow, Poland (GRID:grid.13856.39) (ISNI:0000 0001 2154 3176); University of Rzeszów, Department of Experimental and Clinical Pharmacology, Rzeszow, Poland (GRID:grid.13856.39) (ISNI:0000 0001 2154 3176); University of New South Wales, National Drug and Alcohol Research Centre, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
4 The John Paul II Catholic University of Lublin, Faculty of Medicine, Institute of Biological Sciences, Department of Chemistry, Lublin, Poland (GRID:grid.37179.3b) (ISNI:0000 0001 0664 8391)